Business Updates - Oklo was selected for three DOE Reactor Pilot Program projects, potentially accelerating deployment timelines[17, 20, 21] - Groundbreaking for the Aurora-INL powerhouse was completed in September, with site earthworks beginning in October[18, 26, 27] - Atomic Alchemy targets first operations by July 2026, focusing on isotope production[18, 31] - The company announced a Fuel Recycling Facility as phase I of an advanced fuel center in Tennessee, with a potential investment of up to $168 billion[19, 41, 44] - Oklo signed a Joint Technology Development Agreement with Blykalla and a fuel fabrication and manufacturing partnership with newcleo to collaborate on advanced nuclear ecosystem[17, 48, 50] Financial Highlights - The company's 3Q 2025 loss from operations was $363 million, driven by payroll, general business expenses, and non-cash stock-based compensation[52, 54] - The 3Q 2025 loss before income taxes was $292 million, derived from the loss from operations adjusted for net interest and dividend income of approximately $71 million[52] - Year-to-date 2025 cash used in operating activities totaled $487 million, including a net loss of $642 million, adjusted primarily for non-cash charges[53] - As of September 30, 2025, Oklo had cash and marketable securities totaling $1184 billion, including $4100 million in cash and equivalents and $7735 million in marketable securities[19, 54, 55]

Fiscal Year 2025 Performance - Amdocs achieved revenue growth of 3.1% year-over-year[14] - The company's non-GAAP operating margin increased by 300 basis points year-over-year to 21.4%[14] - Non-GAAP EPS grew by 8.5% year-over-year[14] - Cloud revenue now accounts for over 30% of total revenue, demonstrating double-digit growth[15, 55] - Managed services reached a record 66% of total revenue[16] Q4 FY2025 Results - Revenue reached $1.15 billion, up approximately 2.8% year-over-year[18] - Non-GAAP operating margin was 21.6%, a 290 basis point increase year-over-year[18] - Non-GAAP EPS was $1.83, above the guidance midpoint[18] - The 12-month backlog increased to $4.19 billion, a 3.2% year-over-year increase[18] FY2026 Outlook - The company projects revenue growth of 1.0% to 5.0% year-over-year in constant currency, with a midpoint of 3.0%[41] - Non-GAAP EBIT margin is expected to be 21.3% to 21.9%, with a midpoint of 21.6%, up 20 basis points year-over-year[41] - Non-GAAP EPS growth is projected to be 4.0% to 8.0%, with a midpoint of 6%[41] - Free cash flow is estimated between $710 million and $730 million[41]

Company Overview and Strategy - MicroVision is a leading provider of lidar hardware and software solutions for Automotive, Industrial, Smart Infrastructure, and Robotics markets[7] - The company focuses on high-margin software revenue and revenue-ready lidar products for Automotive and Industrial markets[7] - MicroVision has a strong CAGR potential driven by design RFQs and holds over 700 patents[7] - The company is focused on optimizing near-term applications in the ADAS value chain, particularly L2 and L3 automation[31] Product Portfolio - MicroVision offers MOVIA L, a lidar sensor for Industrial, Smart cities, and short-range automotive applications[8, 21] - MOVIA S is the next evolution of MOVIA L, with a smaller form factor for specific automotive applications[23] - MAVIN N is a MEMS-based lidar sensor with perception software for Auto OEMs and Tier 1s[9, 26] - PERCEPTION software processes data from lidar sensors to enable OEMs to achieve the best driving application[8, 29] Financial Performance - Q3 2024 revenue was $190 thousand[33] compared to $1047 thousand in Q3 2023[33], a decrease primarily due to a delayed order from a non-automotive customer[34] - Adjusted Gross Profit for Q3 2024 was $(32) thousand, resulting in a margin of (17%)[33] - Net cash used in operations in Q3 2024 was $141 million[35] - Total liquidity is $234 million, including $81 million in cash and cash equivalents, $123 million availability under the existing ATM facility, and $30 million availability under the Convertible Note[38]

Company Overview - Quest Resource Holding Corporation (QRHC) is a national provider of waste & recycling solutions to large businesses [1,8] - The company serves a $200B+ North American waste and recycling industry [10] - Quest offers expertise with 130+ waste streams and has a nationwide footprint, delivering services in every zip code in the U S [10] - The company focuses on large clients with complex waste streams, including Fortune 1000 businesses [11,13] Financial Performance - The company has experienced ~20% CAGR in Gross Profit dollars from 2016 to 2024 [14] - Quest's revenue for the trailing twelve months (TTM) ending in Q3 2025 was $261.281 million [10,17] - Gross profit for the same period was $44.162 million [17] - Adjusted EBITDA for TTM 3Q25 was $8.853 million, representing a 3.4% margin [17,78] Business Strategy - Quest employs an asset-light model, differentiating itself from asset-based integrated majors and fragmented players [34,32,36] - The company's platform delivers nationwide waste and recycling services, regulatory compliance, and comprehensive data reporting [24] - Quest aims to improve clients' sustainability, reduce waste footprint, and improve efficiencies & cost control [24]

BAIRD 2025 GLOBAL INDUSTRIALS CONFERENCE UNION PACIFIC CORPORATION JIM VENA – CHIEF EXECUTIVE OFFICER JENNIFER HAMANN – CHIEF FINANCIAL OFFICER Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be 1 Cautionary Information 2 3 Strategic Execution Driving Industry Leading Results SAFETY + SERVICE & OPERATIONAL EXCELLENCE 210 219 215 221 226 238 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25** 86% 89% 94% 99% 98% 100% 89% 96% 93% 97% 100% 100% Q3'24 Q4 ...

Financial Performance & Growth - Q3 2025 total revenue reached $87.3 million, a 69% year-over-year increase[10] - Q3 2025 U S net product sales were $40.7 million, a 31% year-over-year increase[10] - Retail prescription equivalents increased by 9% quarter-over-quarter[11] Market Access & Awareness - Achieved 87% Medicare and 86% commercial approval rates for NEXLETOL and NEXLIZET, with average $29/$36 copays for a 30-day supply[16] - Launched a connected-TV ad campaign on Hulu and Disney+, expected to deliver approximately 18 million impressions targeting adults 50+ with prior statin use[16] Statin Intolerance & Bempedoic Acid - Up to 30% of U S adults experience some degree of statin intolerance[18] - Approximately 29% of patients discontinue their statin within the first year[31] - In the CLEAR Outcomes trial, bempedoic acid demonstrated a 13% relative risk reduction (RRR) in the primary composite endpoint (MACE-4) compared to placebo[48] - In primary prevention patients, bempedoic acid showed a 32% RRR in MACE-4 compared to placebo[52] Clinical Trial Data - CLEAR Outcomes trial showed a 27% RRR in nonfatal myocardial infarction with bempedoic acid compared to placebo[48] - CLEAR Outcomes trial showed a 19% RRR in coronary revascularization with bempedoic acid compared to placebo[48]

AMD Strategy and Vision - AMD aims to drive accelerated growth and deliver shareholder value[3] - The company expects leadership in high-performance and AI computing[3] - AMD anticipates growth and opportunities in the total addressable market[3] - AMD's goal is to deliver significant value to its shareholders[3] Financial Expectations - The presentation includes expectations of AMD's financial plans and long-term financial model, including compound annual growth rate, revenue market share, non-GAAP gross margin, non-GAAP operating margin, non-GAAP effective tax rate, non-GAAP FCF margin and non-GAAP earnings per share[3] - Projected 2025 non-GAAP gross profit and operating profit exclude $800 million inventory and related charges associated with U S export restrictions recognized in Q2'25[5] - AMD uses a projected non-GAAP tax rate of 13-15% for its long-term financial model[5] Meeting Agenda - The AMD Financial Analyst Meeting 2025 includes presentations on AMD's vision and growth strategy, technology strategy, data center leadership, AI leadership, networking, client, graphics, embedded transformation, and financial momentum[6]

THIRD QUARTER EARNINGS CALL NOVEMBER 11, 2025 OXY Cautionary statements Forward-Looking Statements This presentation contains "forward"-doking datements" withint temaning of the "safe factor" frouslisones of the Private Securities Libradition subt od initied to statemen (Ocodential ar Cav ) excectations, belefo; stars or for or of obsings statements in oly e estimates, expectains, probections, probections, robas and unertrianties. Actual seults, screetines materially: Forward-trading and dther strements reg ...

LEGEND Pivotal Cohort Protocol Amendment - The current LEGEND protocol includes changes such as performing a 2nd resection at the lesion site and restaging, which aligns with the standard of care and AUA Guidelines[8] - Enrollment is complete with 125 patients in the pivotal cohort, with 94 patients (75%) enrolled post-amendment and 31 patients (25%) pre-amendment[10, 11] Efficacy Data - Post-protocol amendment, the Intent-to-Treat (ITT) population (N=62) showed a Complete Response (CR) rate of 63% at any time, 56% at 3 months, and 62% at 6 months[14] - Pre-protocol amendment, the ITT population (N=31) showed a CR rate of 55% at any time, 55% at 3 months, and 41% at 6 months[18] - The 6-month CR rate for detalimogene post-amendment is 62%, which is trending competitively with novel products in the industry[25] Tolerability and Safety - In the entire Cohort 1 (n=125), 42.4% of patients experienced at least one Treatment-Related Adverse Event (TRAE), with zero discontinuations due to adverse events[30] - Detalimogene is trending towards best-in-class tolerability compared to other investigational agents and approved products, with a serious TRAE rate of 1.6%[31] Trial Progress and Enrollment - Enrollment rate was heavily skewed to the last 10 months, delaying insights into long-term efficacy[28, 35] - Additional cohorts are in progress, including BCG-Naïve, BCG-Exposed, and Papillary-Only NMIBC, with varying enrollment statuses[33]

Financial Performance - Free cash flow increased by 141% to $920 million in Q3 2025 compared to $381 million in Q3 2024[20] - Headline earnings increased by 185% to $672 million in Q3 2025 compared to $236 million in Q3 2024[20] - Adjusted EBITDA increased by 109% to $1.56 billion in Q3 2025 compared to $746 million in Q3 2024[20] - Basic earnings increased by 200% to $669 million in Q3 2025 compared to $223 million in Q3 2024[20] - The average gold price received increased by 40% to $3,490/oz in Q3 2025 from $2,486/oz in Q3 2024[80] Operational Performance - Gold production increased by 17% to 768,000 oz in Q3 2025 compared to 657,000 oz in Q3 2024[20] - Total cash costs for managed operations increased by 5% year-on-year to $1,244/oz in Q3 2025 from $1,186/oz in Q3 2024[20, 21] - All-in sustaining costs (AISC) for managed operations increased by 6% year-on-year to $1,766/oz in Q3 2025 from $1,665/oz in Q3 2024[79] Mineral Resources and Reserves - The Mineral Resource at the end of the financial year ended 31 December 2024 was estimated using a gold price of $1,900/oz[11] - The Mineral Reserve at the end of the financial year ended 31 December 2024 was estimated using a gold price of $1,600/oz[11]